A Randomized, Double-blind, Placebo-controlled, Multicentre Proof-of-concept Trial of IVA337 in the Treatment of Diffuse Cutaneous Systemic Sclerosis

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Multicentre Proof-of-concept Trial of IVA337 in the Treatment of Diffuse Cutaneous Systemic Sclerosis

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Nov 2017

At a glance

  • Drugs Lanifibranor (Primary)
  • Indications Systemic scleroderma
  • Focus Proof of concept; Therapeutic Use
  • Acronyms FASST
  • Sponsors Inventiva Pharma
  • Most Recent Events

    • 22 Nov 2017 Planned End Date changed from 1 Dec 2017 to 1 Nov 2018.
    • 17 Oct 2017 According to an Inventiva Pharma media release, headline results from this trial are expected in early 2019.
    • 17 Oct 2017 Status changed from recruiting to active, no longer recruiting according to an Inventiva Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top